Why the FDA Should Remove Warning Labels on Hormone Replacement Therapy (HRT)

The Black-Box Warning That Froze a Generation of Women Out of Care

The FDA placed a black-box warning on combined hormone replacement therapy in 2003, one year after the Women's Health Initiative (WHI) published its landmark findings. That warning was appropriate given what was known at the time. The problem is that the science moved on, and the label largely did not.

Millions of women were abruptly taken off HRT after 2002. Prescriptions for menopausal hormone therapy dropped by more than 50 percent in the two years following the WHI publication. Many of those women were in their early 50s, newly menopausal, and well within the window where estrogen therapy carries the most favorable risk-benefit ratio. Undertreated vasomotor symptoms, accelerated bone loss, and genitourinary syndrome of menopause (GSM) followed for a generation of patients whose physicians, understandably, were following the label.

The case for updating or removing the black-box language is not a fringe position. It is the consensus of most major women's health organizations. This article explains the science behind that consensus, who it applies to, and what the label change would mean for you at each life stage.

What the Black-Box Warning Actually Says

The current FDA black-box warning on estrogen and estrogen-progestin products states that these drugs increase the risk of endometrial cancer, cardiovascular events, breast cancer, and dementia, and that they should be used "at the lowest effective dose for the shortest duration consistent with treatment goals."

That language makes no distinction between:

• Oral versus transdermal estrogen (very different clotting risk profiles)
• Conjugated equine estrogen (CEE) versus body-identical estradiol
• Synthetic medroxyprogesterone acetate (MPA) versus micronized progesterone
• Women aged 50 to 59 versus women aged 70 to 79
• Women who are 2 years past menopause versus 20 years past menopause

Collapsing all of those variables into one warning treats very different clinical situations as identical, and that is the core of the problem.

What the WHI Actually Found (and What It Did Not)

The WHI is the most cited justification for the black-box warning, so understanding its actual findings is essential.

The trial enrolled 27,347 women aged 50 to 79. The average age at enrollment was 63. The majority had been post-menopausal for more than 10 years before starting hormone therapy. Many had pre-existing cardiovascular risk factors. This is not the demographic that a clinician would typically prescribe HRT to today.

The Combined Arm

The combined estrogen-plus-progestin arm used oral CEE 0.625 mg plus MPA 2.5 mg daily. It was stopped early in 2002 after a small but statistically significant increase in invasive breast cancer and cardiovascular events. The absolute excess risk of breast cancer was 8 additional cases per 10,000 women per year. That is 0.08 percent per year, or less than 1 additional case per 1,000 women annually.

For context: drinking one alcoholic drink per day is associated with a comparable or greater increase in relative breast cancer risk than the combined HRT regimen used in WHI.

The Estrogen-Only Arm

Women who had undergone hysterectomy received CEE 0.625 mg alone. That arm was not stopped for breast cancer. It actually showed a trend toward fewer breast cancer diagnoses, with a hazard ratio of 0.77, though the finding did not reach statistical significance. The estrogen-only arm deserves far more attention than it typically receives in public discussion.

The Timing Hypothesis

The most significant post-WHI insight is the timing hypothesis, sometimes called the critical window hypothesis. Re-analyses of WHI data, including the WHI Memory Study and long-term follow-up published in JAMA, showed that women who started hormone therapy within 10 years of menopause onset had meaningfully better cardiovascular outcomes than those who started later. The early-start group showed no significant increase in coronary heart disease, and some analyses suggested cardioprotective effects.

This finding is now a cornerstone of The Menopause Society 2022 Hormone Therapy Position Statement, which states directly that hormone therapy is appropriate for healthy symptomatic women under age 60 or within 10 years of menopause who have no contraindications.

Why the Label Has Not Caught Up

If the science has shifted so substantially, why does the FDA label still carry a black-box warning with broadly worded risk language?

The answer involves a mix of regulatory inertia, liability caution, and the political aftermath of the 2002 WHI publication. Updating a black-box warning requires a formal regulatory process, typically involving a citizen petition or manufacturer-initiated label revision, followed by FDA review. No pharmaceutical manufacturer has had a strong commercial incentive to fund that process for off-patent hormone products.

In 2022, The Menopause Society published a position paper specifically calling for label modernization to reflect the timing hypothesis and route-of-administration differences. The American College of Obstetricians and Gynecologists (ACOG) has similarly issued guidance recognizing that the current label does not reflect contemporary evidence for women in early menopause.

What a More Accurate Label Would Include

A scientifically updated HRT label would, at minimum, need to include these distinctions:

By age and time since menopause. The risk-benefit calculation differs substantially between a 52-year-old who stopped her periods 18 months ago and a 72-year-old who stopped 20 years ago. Any honest label must stratify by timing.

By route of administration. Transdermal estradiol (patch, gel, spray) does not undergo first-pass liver metabolism and does not carry the same increased venous thromboembolism (VTE) risk as oral estrogen. The Nurses' Health Study and case-control data from Europe have consistently shown this. A label that treats a 0.05 mg estradiol patch identically to 0.625 mg oral CEE is clinically misleading.

By progestogen type. Micronized progesterone (Prometrium and its generics) has a different receptor profile from synthetic MPA. Data from the E3N cohort study involving more than 80,000 French women found that combined therapy using estrogen plus micronized progesterone did not increase breast cancer risk over four years of follow-up, while estrogen plus synthetic progestins did. This distinction is absent from current labeling.

By indication. GSM (vaginal dryness, dyspareunia, recurrent urinary tract infections) can be treated with low-dose vaginal estrogen that achieves negligible systemic absorption. FDA-approved low-dose vaginal estrogen products still carry the same class warning despite systemic absorption being clinically insignificant at therapeutic doses.

The Real-World Consequences of the Current Label

Outdated warning language has measurable clinical costs for women.

Undertreated vasomotor symptoms. Hot flashes and night sweats are not trivial inconveniences. Severe vasomotor symptoms are associated with disrupted sleep, cognitive difficulties, reduced workplace productivity, and impaired quality of life. A 2023 survey published in Menopause found that women with untreated moderate-to-severe symptoms reported clinically meaningful decrements in sleep and mood scores.

Accelerated bone loss. Estrogen is the primary regulator of bone density in women. In the first five years after menopause, women can lose 5 to 10 percent of bone mass due to falling estrogen levels. HRT is an evidence-based intervention for bone preservation, yet the current label's risk framing discourages its use in exactly the women who could benefit most.

Provider hesitancy. Many primary care providers, internists, and even some OB-GYNs remain reluctant to prescribe HRT because the black-box warning creates liability exposure. A 2021 ACOG survey found widespread gaps in menopause-specific training among physicians, reinforcing the label's chilling effect on prescribing.

Genitourinary syndrome of menopause. GSM affects an estimated 27 to 84 percent of post-menopausal women, yet fewer than 25 percent receive treatment. Low-dose vaginal estrogen, one of the most effective and lowest-risk interventions available, remains stigmatized in part because it carries the same class warning language as systemic HRT.

Sex-Specific Physiology: Why These Distinctions Matter for Women

HRT is a women's health issue. The hormones being replaced, estradiol and progesterone, are the primary sex hormones of the female reproductive system. Their effects on the cardiovascular system, bone, brain, colon, and breast tissue are mediated through sex-hormone receptors that behave differently depending on a woman's age, body composition, and hormonal milieu at the time of treatment initiation.

Women metabolize oral estrogen differently from men metabolizing exogenous estrogen. First-pass hepatic metabolism of oral estradiol generates estrone and estrone sulfate, driving changes in sex-hormone-binding globulin (SHBG), clotting factors, and triglycerides. Transdermal estradiol bypasses this pathway entirely, which is why route of administration is not a trivial pharmacokinetic detail. It is a clinically meaningful sex-specific pharmacological distinction.

Progestogen selection also matters in a sex-specific way. Progesterone receptors in breast tissue differ from those in the uterus. Micronized progesterone has a weaker proliferative effect on breast epithelium than MPA, a difference that has clinical relevance for breast cancer risk and that a properly written label should convey.

Life-Stage Breakdown: Who Benefits and How

Perimenopause (Typically Ages 45 to 52)

During perimenopause, ovarian hormone production becomes erratic. Estradiol levels fluctuate widely before eventually declining. Vasomotor symptoms, irregular periods, mood changes, and sleep disruption are common. HRT, particularly low-dose estradiol with cyclic progestogen to maintain withdrawal bleeding, is an appropriate option for women who are symptomatic and have no contraindications. The timing hypothesis is especially favorable here. This is the window with the best cardiovascular safety profile.

Early Post-Menopause (Within 10 Years of Final Menstrual Period)

This is the group for whom the evidence is most favorable. The Kronos Early Estrogen Prevention Study (KEEPS), a randomized trial of younger post-menopausal women (mean age 52.7), found that low-dose oral conjugated estrogen or transdermal estradiol did not accelerate subclinical atherosclerosis compared with placebo. Bone density was preserved. Vasomotor symptoms improved.

The Menopause Society's 2022 position statement reflects this evidence directly: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture."

Late Post-Menopause (More Than 10 Years Past Final Period or Age 60+)

The risk-benefit profile shifts here. Starting HRT for the first time at age 70 is a different clinical decision from continuing therapy that was started at age 52. For women in this group, cardiovascular and stroke risks are higher, and initiating new therapy requires careful individual assessment. The current label, by applying blanket warnings to all women, fails to communicate this nuance. A good label would say that risk differs by age at initiation, not that all women face identical risks.

Trying to Conceive and Pregnancy

HRT as typically prescribed for menopause (estradiol with or without progestogen) is not indicated during pregnancy. Pregnancy would be an unexpected finding in a woman using HRT, but it is not impossible in a perimenopausal woman who has not yet confirmed ovarian failure. If pregnancy is confirmed in a woman using systemic HRT, the regimen should be reviewed promptly by her clinician.

Low-dose vaginal estrogen is not systematically absorbed in quantities that pose fetal risk, but data in confirmed pregnancy are limited, and use during confirmed pregnancy is not standard practice.

Pregnancy, Lactation, and Contraception (Required Safety Section)

Pregnancy. Systemic HRT products (oral and transdermal estradiol, oral and transdermal estrogen-progestogen combinations) are not approved for use in pregnancy. The FDA classifies them as Pregnancy Category X in older labeling conventions, meaning animal and/or human data show fetal abnormalities and the risks outweigh any possible benefit. Women in perimenopause who retain any possibility of conception and who do not wish to become pregnant should use reliable contraception concurrently with HRT. Ovarian failure cannot be confirmed until 12 consecutive months without a menstrual period. Until that threshold is met, conception remains possible, even if unlikely.

Lactation. Exogenous estrogen reduces milk production and is generally not recommended in breastfeeding women. If a postpartum woman has an indication for hormone therapy (rare, but possible in cases of surgical menopause or premature ovarian insufficiency), the choice of agent, dose, and timing should be guided by a clinician experienced in both lactation and hormone management.

Contraception requirement. Perimenopausal women using HRT should be counseled explicitly that HRT does not provide contraception. Combined oral contraceptives or progestogen-only pills, the levonorgestrel IUD (Mirena), or barrier methods can be used concurrently. The levonorgestrel IUD also provides endometrial protection, making it a practical dual-purpose option for perimenopausal women on estrogen-only systemic therapy who have not had a hysterectomy.

The Conditions That Cleaner Labeling Would Help

Updated HRT labeling would have direct practical effects for women with:

PCOS. Women with polycystic ovary syndrome reach menopause an average of two years later than the general population but face unique metabolic risks in the transition. Clearer labeling would help clinicians individualize therapy without defaulting to a one-size-fits-all risk framework.

Premature ovarian insufficiency (POI). Women diagnosed with POI before age 40 face accelerated cardiovascular risk and early bone loss. Current guidelines from ACOG and the European Society of Human Reproduction and Embryology recommend HRT until at least the average age of natural menopause (around 51 to 52). The current FDA black-box language creates confusion in clinical practice because it does not distinguish POI from age-appropriate menopause.

Genitourinary syndrome of menopause. Low-dose vaginal estrogen should not carry the same warning as systemic therapy. Reclassifying it, or at minimum including explicit label language clarifying that the systemic safety data do not apply to vaginally administered low-dose products, would reduce both patient and provider hesitancy.

Osteoporosis. HRT is one of only a handful of therapies that both prevents and treats osteoporosis in menopausal women. Fear generated by imprecise warning language has pushed women toward bisphosphonates or denosumab when estrogen therapy, particularly in early post-menopause, might be both more effective and more acceptable to the patient.

Female-pattern cardiovascular disease. The cardiovascular event rate in the WHI was concentrated in older women, not in those who started therapy in early menopause. An age-stratified label would more accurately represent the cardiovascular risk for the population most likely to be prescribed HRT today.

What Leading Clinicians and Guidelines Say

Dr. JoAnn Manson, lead investigator of the WHI, has herself stated publicly that the trial results were widely misinterpreted. In a 2013 editorial in JAMA Internal Medicine, Manson and colleagues wrote: "The WHI findings should not be generalized to younger women... The message that hormone therapy is uniformly harmful is not supported by the evidence."

The Menopause Society's 2022 position statement is explicit: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture."

ACOG Practice Bulletin No. 141 notes that the decision to use hormone therapy should be individualized and that the risks documented in the WHI do not necessarily apply to younger, healthier women initiating treatment close to menopause onset.

Who HRT Is Right For (and Who Should Think Twice)

Likely to benefit

• Women aged 50 to 59 with bothersome vasomotor symptoms and no personal history of breast cancer, VTE, stroke, or active liver disease
• Women with GSM, including those who prefer low-dose vaginal estrogen
• Women with POI (any age, any life stage, until at least age 51 to 52)
• Women at elevated fracture risk in early post-menopause who prefer HRT to other bone-protective agents

Requires careful individual assessment

• Women aged 60 to 65 initiating HRT for the first time
• Women with a BRCA1/2 mutation (evidence is nuanced; BRCA carriers may still be candidates for short-term HRT if symptomatic, though oncology input is important)
• Women with migraines with aura (transdermal estrogen may be preferable to oral)
• Women with a first-degree family history of breast cancer but no personal history

Generally not appropriate (current contraindications)

• Active or recent breast cancer
• Active thromboembolic disease or high inherited thrombophilia risk (e.g., Factor V Leiden homozygous)
• Unexplained vaginal bleeding
• Active liver disease with impaired function
• Confirmed or suspected pregnancy (systemic HRT)